Table 1.

Pharmacokinetic parameters of cenerimod estimated following single-dose (Study 1), o.d. for 35 days (Study 2), and single-dose administration in fed or fasted conditions (Study 3).

		Day 1					Day 35
	Dose (mg)	Cmax (ng/mL)	tmax (h)	AUC0–24 (ng·h/mL)	AUC0–∞ (ng·h/mL)	t1/2 (h)	Cmax (ng/mL)	tmax (h)	AUC0–24 (ng·h/mL)	AUC0–∞ (ng·h/mL)	t1/2 (h)	R
												Cmax	AUC0–24
Study 1	1	3.9	5.0	69.3	610	172	NC
		(2.9–5.2)	(4.0–8.0)	(52.4–90.3)	(504–735)	(125–232)
	3	13.1	6.0	232	2070	184
		(10.1–16.8)	(4.0–8.0)	(181–292)	(1470–2790)	(153–220)
	10	46.7	6.0	823	8030	199
		(42.4–51.3)	(6.0–8.0)	(732–923)	(6700–9550)	(188–211)
	25	122	6.2	2030	18,700	170
		(89.5–161.0)	(4.0–8.0)	(1480–2700)	(14,100–24,200)	(134–213)
Study 2	0.5	2.4	5.0	41.1	NC	NC	13.1	4.3	269	3390	283	5.5	6.6
		(2.0–2.8)	(4.0–6.0)	(37.0–45.5)			(9.8–17.6)	(2.5–8.0)	(198–366)	(2050–5590)	(210–381)	(4.6–6.5)	(5.3–8.1)
	1	5.1	5.0	83.5			34.2	5.0	720	9750	436	6.7	8.6
		(4.4–5.9)	(4.0–6.0)	(72.9–95.6)			(26.8–43.7)	(2.5–8.0)	(560–926)	(7270–13,100)	(359–529)	(5.5, 8.3)	(7.3, 10.2)
	2	7.7	6.0	134			43.9	6.0	925	11,900	415	5.7	6.9
		(6.1–9.7)	(4.0–8.0)	(109–164)			(35.9–53.8)	(6.0–8.0)	(767–1120)	(8340–16,900)	(358–481)	(4.3, 7.5)	(5.2, 9.3)
	4	18.9	5.0	301			98.7	6.0	2100	31,900	539	5.2	7
		(14.4–24.9)	(4.0–6.0)	(238–380)			(68.0–143.0)	(2.5–12.0)	(1390–3170)	(21,200–48,000)	(492–591)	(4.4, 6.3)	(5.6, 8.7)
Study 3	1 fasted	4.73	6.0	83.7	649	200	NC
		(4.1, 5.5)	(6.0–8.0)	(71.9, 97.4)	(507, 832)	(166, 239)
	1 fed	4.35	7.0	75.5	630	191
		(3.5, 5.4)	(6.0–12.0)	(62.0, 91.9)	(498, 798)	(157, 232)

The data are expressed as geometric mean (95% confidence interval), execpt t_max that is expressed as median (range). AUC_0–∞: area under the curve from time zero to infinity, AUC_0–24: area under the curve from time zero to 24 h, C_max: maximum plasma concentration, NC: not calculated, R ratio Day35/Day1, t_1/2: terminal half-life, t_max: time to maximum plasma concentration.